The solid-state and morphological characteristics of particles generated from solution-based metered dose inhalers: Influence of ethanol concentration and intrinsic drug properties

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 443, Issue , 2014, Pages 345-355

  Zhu, Bing ^a   Traini, Daniela ^a,b   Lewis, David A ^c   Young, Paul ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Aerosol performance; Caffeine; Corticosteroid; Morphology; Particle formation; Solution based pMDI

Indexed keywords

AEROSOLS; BIOCHEMISTRY; CAFFEINE; DRUG DOSAGE; DRUG PRODUCTS; DRYING; METEOROLOGICAL INSTRUMENTS; MORPHOLOGY; PARTICLE SIZE ANALYSIS; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; THERMOANALYSIS;

ACTIVE PHARMACEUTICAL INGREDIENTS; AEROSOL PARTICLE SIZE DISTRIBUTION; AEROSOL PERFORMANCE; CORTICOSTEROID; MASS MEDIAN AERODYNAMIC DIAMETERS; PARTICLE FORMATIONS; PRESSURIZED-METERED DOSE INHALERS; SOLUTION-BASED PMDI;

ETHANOL;

ALCOHOL; BECLOMETASONE DIPROPIONATE; CAFFEINE; FLUTICASONE PROPIONATE;

AEROSOL; ARTICLE; GLASS TRANSITION TEMPERATURE; METERED DOSE INHALER; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SOLUBILITY; THERMAL ANALYSIS;

EID: 84890323628     PISSN: 09277757     EISSN: 18734359     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2013.11.034     Document Type: Article

References (42)

1. Smyth H.D.C. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Advanced Drug Delivery Reviews 2003, 55:807-828.
2. Vervaet C., Byron P.R. Drug-surfactant-propellant interactions in HFA-formulations. International Journal of Pharmaceutics 1999, 186:13-30.
3. Lewis D. Intrinsic particle size distribution: a new metric to guide the design of HFA solution pMDIs. RRD Europe 2013, 2013(1):175-184.
4. Stein S.W., Myrdal P.B. A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions. Journal of Pharmaceutical Sciences 2004, 93:2158-2175.
5. Gupta A., Stein S.W., Myrdal P.B. Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers. Journal of Aerosol Medicine 2003, 16:167-174.
6. Zhu B., Traini D., Chan H.-K., Young P. The effect of ethanol on the formation and physico-chemical properties of particles generated from solution-based pressurized metered dose inhalers. Drug Development and Industrial Pharmacy 2013, 10.3109/03639045.03632012.03728230.
7. Buttini F., Grainger C.I., Jones S.A., Royall P.G., Martin P.G., Forbes B. Characterization of particles emitted from two formulations of beclomethasone dipropionate solutoin metered dose inhalers. Respiratory Drug Delivery 2008, 2008(2):581-584.
8. Ganderton D., Lewis D., Davies R., Meakin B., Church T. The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler. Respiratory Medicine 2003, 97:S4-S9.
9. Brambilla G., Ganderton D., Garzia R., Lewis D., Meakin B., Ventura P. Modulation of aerosol clouds produced by pressurised inhalation aerosols. International Journal of Pharmaceutics 1999, 186:53-61.
10. Lewis D. Metered-dose inhalers: actuators old and new. Expert Opinion on Drug Delivery 2007, 4:235-245.
11. Jetmalani K., Young P., Smith T., Stewart P., Traini D. Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers. Drug Development and Industrial Pharmacy 2012, 1-8.
12. El-Gendy N., Pornputtapitak W., Berkland C. Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. European Journal of Pharmaceutical Sciences 2011, 44(4):522-533.
13. Westmeier R., Steckel H. Combination particles containing salmeterol xinafoate and fluticasone propionate: formulation and aerodynamic assessment. Journal of Pharmaceutical Sciences 2008, 97:2299-2310.
14. Dong J.X., Li Q., Tan Z.C., Zhang Z.H., Liu Y. The standard molar enthalpy of formation, molar heat capacities, and thermal stability of anhydrous caffeine. Journal of Chemical Thermodynamics 2007, 39:108-114.
15. Descamps M., Correia N.T., Derollez P., Danede F., Capet F. Plastic and glassy crystal states of caffeine. Journal of Physical Chemistry B 2005, 109:16092-16098.
16. Sun C.C., Hou H. Improving mechanical properties of caffeine and methyl gallate crystals by cocrystallization. Crystal Growth and Design 2008, 8:1575-1579.
17. Abdel-Halim H., Traini D., Hibbs D., Gaisford S., Young P. Modelling of molecular phase transitions in pharmaceutical inhalation compounds: an in silico approach. European Journal of Pharmaceutics and Biopharmaceutics 2011, 78:83-89.
18. Bouhroum A., Burley J.C., Champness N.R., Toon R.C., Jinks P.A., Williams P.M., Roberts C.J. An assessment of beclomethasone dipropionate clathrate formation in a model suspension metered dose inhaler. International Journal of Pharmaceutics 2010, 391:98-106.
19. Grainger C., Saunders M., Buttini F., Telford R., Merolla L., Martin G., Jones S., Forbes B. Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence. Molecular Pharmaceutics 2012, 9:563-569.
20. Ramos J.J.M., Correia N.T., Diogo H.P., Descamps M. Dielectric study of the slow motional processes in the polymorphic states of anhydrous caffeine. Journal of Physical Chemistry B 2006, 110:8268-8273.
21. Bothe H., Cammenga H. Composition, properties, stability and thermal dehydration of crystalline caffeine hydrate. Thermochimica Acta 1980, 40:29-39.
22. Traini D., Young P.M., Price R., Rogueda P. A novel apparatus for the determination of solubility in pressurized metered dose inhalers. Drug Development and Industrial Pharmacy 2006, 32:1159-1163.
23. Lewis D.A., Ganderton D., Meakin B.J., Brambilla G. Theory and practice with solution systems. RDD 2004, IX:109-116.
24. Keller M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. International Journal of Pharmaceutics 1999, 186:81-90.
25. Williams R.O., Liu J. Influence of formulation additives on the vapor pressure of hydrofluoroalkane propellants. International Journal of Pharmaceutics 1998, 166:99-103.
26. Ju D., Shrimpton J., Hearn A. The effect of reduction of propellant mass fraction on the injection profile of metered dose inhalers. International Journal of Pharmaceutics 2010, 391:221-229.
27. Dunbar C. Atomization mechanims of the pressurized metered dose inhaler. Particulate Science and Technology 1997, 15:253-271.
28. Clark A.R. Metered atomisation for respiratory drug delivery 1991, Loughborough University, UK, (PhD thesis).
29. Crosland B.M., Johnson M.R., Matida E.A. Characterization of the spray velocities from a pressurized metered-dose inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2009, 22:85-98.
30. Wigley G., Versteeg H., Hodson D. Near-orifice PDA measurements and atomisation mechanism of a pharmaceutical pressurised metered dose inhaler. Zaragoza 2002, 9:11.
31. Stein S.W., Myrdal P.B. The relative influence of atomization and evaporation on metered dose inhaler drug delivery efficiency. Aerosol Science and Technology 2006, 40:335-347.
32. Dalby R.N., Byron P.R. Comparison of output particle size distributions from pressurized aerosols formulated as solutions or suspensions. Pharmaceutical Research 1988, 5:36-39.
33. Smyth H., Brace G., Barbour T., Gallion J., Grove J., Hickey A.J. Spray pattern analysis for metered dose inhalers: effect of actuator design. Pharmaceutical Research 2006, 23:1591-1596.
34. McKenzie L., Oliver M. Evaluation of the particle formation process after actuation of solution MDIs. Journal of Aerosol Medicine 2000, 13:59.
35. Tajber L., Corrigan D., Corrigan O., Healy A. Spray drying of budesonide, formoterol fumarate and their composites-I, physicochemical characterisation. International Journal of Pharmaceutics 2009, 367:79-85.
36. Tarara T.E., Hartman M.S., Gill H., Kennedy A.A., Weers J.G. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharmaceutical Research 2004, 21:1607-1614.
37. Craig D.Q.M., Royall P.G., Kett V.L., Hopton M.L. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. International Journal of Pharmaceutics 1999, 179:179-207.
38. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. Journal of Pharmaceutical Sciences 1997, 86:1-12.
39. Brambilla G., Church T., Lewis D., Meakin B. Plume temperature emitted from metered dose inhalers. International Journal of Pharmaceutics 2011, 405:9-15.
40. Gupta A., Myrdal P.B. Novel method for the determination of solubility in aerosol propellants. Journal of Pharmaceutical Sciences 2004, 93:2411-2419.
41. Bakhbakhi Y., Charpentier P., Rohani S. The solubility of beclomethasone-17,21-dipropionate in selected organic solvents: experimental measurement and thermodynamic modeling. Organic Process Research & Development 2009, 13:1322-1326.
42. Bustamante P., Navarro J., Romero S., Escalera B. Thermodynamic origin of the solubility profile of drugs showing one or two maxima against the polarity of aqueous and nonaqueous mixtures: niflumic acid and caffeine. Journal of Pharmaceutical Sciences 2002, 91:874-883.